Venous creatinine as a biomarker for loss of fat-free mass and disease progression in patients with amyotrophic lateral sclerosis.
Cory J HoldomMark R Janse van MantgemRuben P A van EijkStephanie L HoweLeonard H van den BergPamela A McCombeRobert David HendersonShyuan T NgoFrederik J SteynPublished in: European journal of neurology (2021)
Venous creatinine is decreased in ALS and declines alongside a decline in fat-free mass over the course of the disease, and may serve as a practical marker to monitor the change of fat-free mass in patients with ALS. This could inform clinical care and provide an alternative endpoint for the evaluation of therapeutic interventions that focus on slowing the loss of fat-free mass and disease progression in ALS.